Travel Health Evidence

Praktískt

Matur erlendis með celiaki eða fæðuofnæmi

Tungumálahindrun breytir stjórnaðri aðstöðu í happdrætti. Lausnin er að mestu leyti skipulagsleg, og það er þess virði að gera áður en þú ferð.

Uppfært 2 mín lesning 40 tilvísanir Sönnunargildi 3/5

Biðsvæði flugvalla með röðum af sætum og dagsbirtu ofan frá
Jwh · CC BY-SA 3.0 lu · Wikimedia Commons

Hvað reglur ESB veita þér

Fjórtán helstu ofnæmisvöldum — þar á meðal kornum sem innihalda glúten — verður að tilkynna um í ESB, í pakkaðri fæðu og í matþjónustu. Reglurnar eru nógu samræmdar að ferðamaður með celiaki sem fer milli aðildarríkja stendur frammi fyrir sama merkingarkerfi, sem er veruleg og vanmetin kostur.

Það sem breytist er framkvæmd, hvernig matþjónusta tilkynnir (munnlega, á matseðli, í möppu), og menningarleg þekking á aðstæðunni. Sum lönd hafa mikla almenningsvitund um celiaki; önnur líta á það sem val.

Praktíska kerfið

  1. Fáðu þýðingarkort á staðbundnu tungumáli, þar sem aðstaðan er tilkynnt læknisfræðilega, nefnd er hvað þarf að forðast, og minnst er á sameiginlegar frystur og yfirborð. Kort fer til eldhússins; talað setning fer ekki.
  2. Lærðu að lesa innihaldslýsinguna, ekki tungumálið. Ofnæmisvöld eru áhersluð typografískt um ESB, svo þú getur fundið þau án þess að lesa restina.
  3. Bókaðu gistingu með ísskáp og ketli. Það breytir erfiðum ferð í venjulega.
  4. Berðu með þér öruggt fæði fyrir ferðadaga. Flugvellir, stöðvar og langar ferðir eru þar sem fólk festist.
  5. Finndu staðbundna celiaki- eða ofnæmisfélagið. Flest Evrópuríki hafa eitt, nokkur birta lista yfir staði.
  6. Taktu nægilega lyf — þar á meðal adrenalín sjálfspennara þar sem við á — og berðu með þér lyfseðil.

Tryggingar og skjöl

Athugaðu að ferðatryggingin þín nær yfir aðstöðuna þína, og berðu með þér skjöl um öll lyf í upprunalegum umbúðum með lyfseðli. Innan ESB nær Evrópska heilbrigðistryggingakortið yfir nauðsynlega ríkisveitta meðferð, sem er ekki það sama og ferðatrygging og kemur ekki í staðinn fyrir það.

Algengar spurningar

Eru þýðingaspjöld í raun gagnleg?
Já, meira en að tala. Hægt er að rétta eldhúsinu spjald, en þar eru ákvarðanirnar teknar.
Hvaða Evrópulönd eru auðveldust fyrir fólk með glútenóþol?
Vitund er breytilegri en reglusetning. Landsbundin glútenóþolsfélög eru besta heimildin sem stendur, frekar en nokkur alhæfing.
Get ég tekið lyfin mín yfir landamæri?
Almennt já, í upprunalegum umbúðum með lyfseðilsbréfi. Athugaðu sérstaklega ávana- og fíkniefni sem eru undir eftirliti.
Hvað ef ég fæ í mig glúten erlendis?
Meðhöndlaðu einkenni og vökvun. Engin meðferð er til við snertingu við glúten — sjá glútenóþolssíðuna okkar.
Inni í þröngum flugvél með ofanlokum og þremur sætum í röð
Aykleinman (talk) · Public domain · Wikimedia Commons

Tengd lesefni

Sönnunargrunnur þessa síðu Staflaður súlurit sem sýnir samsetningu 26 ritgerða sem vísað er til á þessari síðu eftir rannsóknartegund. 11855meta-analysis (11)randomised trial (8)review (5)other (5)
29 ritgerðir, 1987–2026. Þetta er blanda af bæði rannsóknum og samantektum, sem er sú staða sem kröfu um orsök er skynsamlegt að gera. Heimild: tilvísunarlisti þessarar síðu, hér að neðan.

Tilvísanir

Hver tilvísun hér að neðan tengist upprunalegu ritrýndu skjalinu á PubMed eða í gegnum DOI. Ekkert hér er staðgengill fyrir læknisfræðilega ráðgjöf.

  1. Selected laboratory-based biomarkers for assessing vitamin A deficiency in at-risk individuals Gannon BM, Huey SL, Mehta NH, et al. · The Cochrane database of systematic reviews · 2025 · Meta-analysis DOIPubMed 40433851Full text
  2. Towards shortening the duration of antibiotic therapy for Lyme borreliosis: a systematic review and meta-analysis Raffetin A, Henningsson AJ, Ornstein K, et al. · Infection · 2025 · Meta-analysis DOIPubMed 40246800
  3. Non-pharmacological interventions designed to support carriers of multi-drug-resistant organisms (MDROs): a systematic literature review Gaube S, Pan M, Rath A, et al. · The Journal of hospital infection · 2025 · Systematic review DOIPubMed 40816599
  4. Risk of anaphylaxis on commercial flights Turner PJ · Current opinion in allergy and clinical immunology · 2025 · Systematic review DOIPubMed 40643054Full text
  5. How Common Are Allergic Reactions During Commercial Flights? A Systematic Review and Meta-Analysis Turner PJ, Mamula J, Laktabi J, et al. · The journal of allergy and clinical immunology. In practice · 2023 · Meta-analysis DOIPubMed 37507067
  6. Skin care interventions in infants for preventing eczema and food allergy Kelleher MM, Cro S, Cornelius V, et al. · The Cochrane database of systematic reviews · 2021 · Meta-analysis DOIPubMed 33545739Full text
  7. Whole-cell pertussis vaccine in early infancy for the prevention of allergy in children Perez Chacon G, Ramsay J, Brennan-Jones CG, et al. · The Cochrane database of systematic reviews · 2021 · Systematic review DOIPubMed 34693993Full text
  8. The effectiveness of anti-inflammatory and anti-seizure medication for individuals with single enhancing lesion neurocysticercosis: A meta-analysis and expert group-based consensus recommendations Abraham A, Bustos JA, Carabin H, et al. · PLoS neglected tropical diseases · 2021 · Meta-analysis DOIPubMed 33788843Full text
  9. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement Vultaggio A, Agache I, Akdis CA, et al. · Allergy · 2020 · Clinical guideline DOIPubMed 32500526Full text
  10. Exit and Entry Screening Practices for Infectious Diseases among Travelers at Points of Entry: Looking for Evidence on Public Health Impact Mouchtouri VA, Christoforidou EP, An der Heiden M, et al. · International journal of environmental research and public health · 2019 · Systematic review DOIPubMed 31766548Full text
  11. Frequency, severity and causes of unexpected allergic reactions to food: a systematic literature review Versluis A, Knulst AC, Kruizinga AG, et al. · Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2015 · Systematic review DOIPubMed 24766413
  12. EAACI food allergy and anaphylaxis guidelines: managing patients with food allergy in the community Muraro A, Agache I, Clark A, et al. · Allergy · 2014 · Clinical guideline DOIPubMed 24905609
  13. Source attribution of human campylobacteriosis using a meta-analysis of case-control studies of sporadic infections Domingues AR, Pires SM, Halasa T, et al. · Epidemiology and infection · 2012 · Meta-analysis DOIPubMed 22214729
  14. Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies Chinthrajah RS, Kulis M, Jones SM, et al. · The Journal of allergy and clinical immunology · 2026 · Randomised controlled trial DOIPubMed 41238005Full text
  15. PrecISE-a biomarker-stratified adaptive trial of 5 interventions in severe asthma: Final protocol and the baseline cohort Denlinger LC, Israel E, Moore WC, et al. · The Journal of allergy and clinical immunology · 2026 · Randomised controlled trial DOIPubMed 41707916Full text
  16. Early-life peanut oral immunotherapy associated with long-term ingestion and immunologic changes Dantzer JA, Virkud YV, Cox AL, et al. · The Journal of allergy and clinical immunology · 2026 · Randomised controlled trial DOIPubMed 42167657Full text
  17. Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial Morgan WJ, Mauger DT, Bacharier LB, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 42705251
  18. Effects of pregnancy and lactation prebiotics supplementation on infant allergic disease: A randomized controlled trial Palmer DJ, Cuthbert AR, Sullivan TR, et al. · The Journal of allergy and clinical immunology · 2025 · Randomised controlled trial DOIPubMed 39173718
  19. A pediatric randomized, controlled trial of German cockroach subcutaneous immunotherapy Zoratti E, Wood R, Pomés A, et al. · The Journal of allergy and clinical immunology · 2024 · Randomised controlled trial DOIPubMed 38718950Full text
  20. Double-Blind, Placebo-Controlled Study of E-B-FAHF-2 in Combination With Omalizumab-Facilitated Multiallergen Oral Immunotherapy Wang J, Wood RA, Raymond S, et al. · The journal of allergy and clinical immunology. In practice · 2023 · Randomised controlled trial DOIPubMed 37087097Full text
  21. One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial Kliewer KL, Gonsalves N, Dellon ES, et al. · The lancet. Gastroenterology & hepatology · 2023 · Randomised controlled trial DOIPubMed 36863390Full text
  22. Impact of an Intervention on Healthy Offerings and Allergenic Food Management in Restaurants: A Parallel Randomized Controlled Study Tarro L, Mandracchia F, Queral J, et al. · Nutrients · 2023 · Randomised controlled trial DOIPubMed 38068728Full text
  23. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial Jackson DJ, Bacharier LB, Gergen PJ, et al. · Lancet (London, England) · 2022 · Randomised controlled trial DOIPubMed 35964610Full text
  24. Randomized, double-blind, placebo-controlled, food allergy challenge to olestra snacks Burks AW, Christie L, Althage KA, et al. · Regulatory toxicology and pharmacology : RTP · 2001 · Randomised controlled trial DOIPubMed 11603960
  25. Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology: An EAACI Position Paper Pascal M, Chauhan J, Knol E, et al. · Allergy · 2025 · Review DOIPubMed 40503572Full text
  26. The epithelial barrier theory and its associated diseases Sun N, Ogulur I, Mitamura Y, et al. · Allergy · 2024 · Review DOIPubMed 39370939Full text
  27. Scope and applicability of social-ecological resilience to antimicrobial resistance Wernli D, Søgaard Jørgensen P, Parmley EJ, et al. · The Lancet. Planetary health · 2023 · Review DOIPubMed 37438004
  28. Safe Living Following Solid Organ Transplantation Blair BM · The Surgical clinics of North America · 2019 · Review DOIPubMed 30471739
  29. Travel Medicine Leung DT, LaRocque RC, Ryan ET · Annals of internal medicine · 2018 · Review DOIPubMed 29297035
  30. IgE in the diagnosis and treatment of allergic disease Platts-Mills TAE, Schuyler AJ, Erwin EA, et al. · The Journal of allergy and clinical immunology · 2016 · Review DOIPubMed 27264001Full text
  31. The restaurant syndromes Settipane GA · New England and regional allergy proceedings · 1987 · Review DOIPubMed 3302666
  32. Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 The Lancet. Infectious diseases · 2026 · Journal article DOIPubMed 41412141
  33. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage: The Global Burden of Disease Study 2021 Rautalin I, Volovici V, Stark BA, et al. · JAMA neurology · 2025 · Journal article DOIPubMed 40406922Full text
  34. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023 Lancet (London, England) · 2025 · Journal article DOIPubMed 41092927Full text
  35. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 Lancet (London, England) · 2025 · Journal article DOIPubMed 41092926Full text
  36. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 Lancet (London, England) · 2025 · Journal article DOIPubMed 41092928Full text
  37. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 The Lancet. Neurology · 2024 · Journal article DOIPubMed 39304265Full text
  38. Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study Ozonoff A, Jayavelu ND, Liu S, et al. · Nature communications · 2024 · Journal article DOIPubMed 38172101Full text
  39. Formononetin inhibits IgE by huPlasma/PBMCs and mast cells/basophil activation via JAK/STAT/PI3-Akt pathways Musa I, Wang ZZ, Yang N, et al. · Frontiers in immunology · 2024 · Journal article DOIPubMed 39221239Full text
  40. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019 Shin YH, Hwang J, Kwon R, et al. · Allergy · 2023 · Journal article DOIPubMed 37431853Full text

Þessi síða var þýdd sjálfkrafa úr ensku. Tilvísanir og tölur eru óbreyttar. Lestu upprunalega ensku ef eitthvað hljómar undarlega. Lestu upprunalega ensku